Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2016; 22(47): 10316-10324
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10316
Evolving management of metaplasia and dysplasia in Barrett's epithelium
Richard P T Evans, Moustafa Mabrouk Mourad, Simon G Fisher, Simon R Bramhall
Moustafa Mabrouk Mourad, Simon G Fisher, Simon R Bramhall, Richard PT Evans, Department of Surgery, the Wye Valley NHS Trust, HR1 2ER Hereford, United Kingdom
Author contributions: Evans RPT designed the study; Evans RPT, Mourad MM and Fisher SG collected, analysed, interpreted the data, and drafted the article; Evans RPT and Bramhall SR designed the conception, critically revised the manuscript for important intellectual content, and made the final approval of the version to be published.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Dr. Simon R Bramhall, Department of Surgery, the Wye Valley NHS Trust, Vaughan Building/Ruckhall La, Hereford HR1 2ER, United Kingdom.
Telephone: +44-7976-278549 Fax: + 44-1432-364102
Received: September 20, 2016
Peer-review started: September 20, 2016
First decision: October 10, 2016
Revised: October 30, 2016
Accepted: December 2, 2016
Article in press: December 2, 2016
Published online: December 21, 2016
Core Tip

Core tip: Barrett's esophagus is a premalignant condition. Its malignant sequela, esophagogastric junctional adenocarcinoma, has a mortality rate of over 85%. The risk of developing esophageal adenocarcinoma in people who have Barrett's esophagus has been estimated to be 6-8 per 1000 person-years. Early identification of Barrett’s and adjusted management is very important to decrease oesophageal cancer related deaths worldwide.